Introduction {#S1}
============

Non-alcoholic fatty liver disease (NAFLD) is a progressive disease of the liver that ranges on a wide pathological spectrum from hepatic steatosis to a more severe non-alcoholic steatohepatitis (NASH) phenotype, which can progress to fibrosis and cirrhosis ([@B8]). Numerous factors are involved in the progression of NAFLD, including changes in lipid metabolism, insulin resistance, inflammatory cytokines, and oxidative stress ([@B7]). NAFLD has a high incidence rate, with reports in the general population ranging from 10 to 30% and as high as 80 to 100% in obesity and morbid obesity ([@B73]; [@B10]). NAFLD progression is the most rapidly increasing indication for liver transplantation in the United States ([@B76]) and now can be considered a multisystem disease affecting many extra-hepatic organs. Indeed, NAFLD is an independent risk factor for cardiovascular, liver-related, and all-cause mortality ([@B67]; [@B65]), and doubles the risk of type 2 diabetes development ([@B41]). Currently, there are no FDA-approved pharmacological treatments for NAFLD.

Hepatic Mitochondrial Dysfunction and NAFLD {#S1.SS1}
-------------------------------------------

While the mechanisms behind NAFLD development have not been fully elucidated, mounting evidence suggests that hepatic mitochondrial dysfunction is tightly linked to disease progression ([@B9]; [@B49]; [@B42]). Characteristics of hepatic mitochondrial dysfunction in the setting of NAFLD/NASH progression include decreased electron transport chain (ETC) content, abnormal mitochondrial morphology, and reduced respiration and β-oxidation ([@B75]). However, there is some controversy surrounding this timing of hepatic mitochondrial dysfunction during NAFLD development. In rodent models, a decline in hepatic mitochondrial function is observed early in fatty liver development; our group has shown that mitochondrial dysfunction in the liver even precedes hepatic steatosis development ([@B51]). In human NAFLD/NASH development it is not as clear -- previous studies have reported either a compensatory increase or no change in hepatic mitochondrial function and TCA cycle flux during fatty liver development in humans ([@B66]; [@B50]; [@B14]), but this is lost during NASH progression ([@B39]; [@B24]). Moreover, NASH patients present with porous mitochondria and elevated hepatic oxidative stress, along with impaired mitochondrial biogenesis and decreased ETC complexes ([@B24]). NAFLD is also associated with increased mitochondrial membrane potential, electron leak, and elevated ROS production ([@B53]). In fact, NASH patients have lower maximal hepatic mitochondrial respiration and increased proton leakage, despite having higher mitochondrial mass, and this is associated with elevated hepatic oxidative stress, greater H~2~O~2~ emission, and reduced anti-oxidant capacity ([@B24]). Despite the debate over its timing during NAFLD/NASH development, mitochondrial dysfunction is clearly implicated in exacerbating disease progression, and therapies that target hepatic mitochondria may provide novel avenues for NAFLD/NASH treatment. However, the mechanisms behind hepatic mitochondrial function, and ultimately NAFLD development are unresolved. In this review, we posit that one potential mediator of hepatic mitochondrial dysfunction and NAFLD progression is the loss of endothelial nitric oxide synthase (eNOS), and its product nitric oxide (NO), due to this enzyme's well-established role in metabolic health and mitochondrial dynamics (discussed later). We will focus on the roles of hepatocellular eNOS and NO in maintaining a healthy mitochondrial pool within the liver and how this may pertain to NAFLD pathogenesis.

Nitric Oxide {#S1.SS2}
------------

Since the discovery of a role for NO in maintaining cardiovascular homeostasis by Furchgott, Ignarro, and Murad, for which they shared a Nobel Prize in Physiology or Medicine in 1998, numerous physiological and pathophysiological functions of NO have been described. NO is an autocrine and paracrine signaling gas that has many diverse functions and molecular targets, such as regulating neurotransmission, vascular tone, gene transcription, mRNA translation, and post-translational modification \[reviewed in detail ([@B31]; [@B15])\]. NO is produced by the nitric oxide synthase (NOS) enzyme, which consists of three isoforms; neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). All three isoforms catalyze the production of NO by converting L-arginine to L-citrulline, with oxygen, reduced nicotinamide-adenine-dinucleotide phosphate (NADPH), and tetrahydrobiopterin (BH4) used as essential substrates and cofactors ([@B5]). The biological role of NO is often concentration dependent; pathological levels (μM) are typically produced by iNOS as an immune defense mechanism when macrophages are induced leading to cytotoxicity. Alternatively, physiological levels of NO (nM) are constitutively produced by nNOS and eNOS. The effects of NO are largely concentration dependent, and as the concentration of a gas reduces by a decay constant as the distance from its point of origin, the enzymes that produce NO are poised to be a robust cellular tool in tailoring subcellular responses as needed. This is most notably apparent in the well characterized role of eNOS in vascular endothelial cells, where it is located at the luminal plasma membrane in order to rapidly increase its production of NO and cause vasodilation in response to increases in shear stress. Since its initial discovery as a potent vasodilator in endothelial cells, eNOS has been shown to provide important regulatory functions in a variety of tissues.

eNOS Activation {#S1.SS3}
---------------

Activity of eNOS is largely controlled by phosphorylation at multiple sites that can positively or negatively influence its activity. Seven phosphorylation sites have been characterized, including two stimulatory sites (S615, S1177), three inhibitory sites (S114, T495, Y657), and two sites for which the influence on eNOS activity is undetermined (Y81, S633) ([@B4]; [@B40]). Of particular interest is that eNOS is activated via S1177 and S615 phosphorylation by AMP-activated protein kinase (AMPK) ([@B11]), serine/threonine protein kinase (Akt) ([@B16]), and protein kinase A (PKA) ([@B36]). These data highlight the ability for eNOS activity to be modulated both by external stimuli (Akt, PKA) as well as the internal metabolic state (AMPK) of the cell. Many NAFLD therapeutics target AMPK activation due its purported benefits on *de novo* lipogenesis inhibition, increased fatty acid oxidation, and stimulation of mitochondrial biogenesis ([@B63]). Interestingly, activation of AMPK by exercise ([@B28]) or metformin ([@B79]) does not occur in eNOS knockout (KO) mice; whereas, NO donors can stimulate AMPK phosphorylation ([@B78]). This lends support to the notion that eNOS may exert its metabolic benefits in an AMPK-dependent manner and play an important role in scenarios where metabolism and/or energy state is perturbed, i.e., obesity/NAFLD ([Figure 1](#F1){ref-type="fig"}).

![The regulation of eNOS by the kinases AMP-activated protein kinase (AMPK), serine/threonine protein kinase (Akt), and protein kinase A (PKA), and some of the downstream metabolic consequences of eNOS modulation by these signals. (1) In response to external and internal stimuli, eNOS is activated by the kinases AMPK, Akt, and PKA at the major phosphorylation sites -- S1177 and S615. These kinases can also be downregulated during NAFLD/obesity. (2) Upon eNOS activation, nitric oxide (NO) is produced as a byproduct during the conversion of L-arginine to L-citrulline. (3) It is unknown whether eNOS-derived NO is required for the metabolic benefits of AMPK activation. (4) Activation of AMPK results in decreased *de novo* lipogenesis and increased fatty acid oxidation and mitochondrial biogenesis. (5) Other downstream effects of eNOS-derived NO upon activation of eNOS.](fphys-11-00767-g001){#F1}

The Link Between eNOS and NAFLD {#S1.SS4}
-------------------------------

Mounting evidence from whole body eNOS KO models demonstrate its importance for metabolic health. Mice lacking eNOS have elevated FFAs and triglycerides, as well as reduced mitochondrial content and beta-oxidation in skeletal muscle ([@B26]). Additionally, eNOS KO mice develop insulin resistance at the level of the liver and other peripheral tissues ([@B59]), and accumulate more liver fat compared to WT mice on a high-fat diet ([@B45]). Taken together, these data clearly outline an important role for eNOS in metabolic health. In the context of NAFLD development, the vast majority of studies examining eNOS have focused on its role in regulation of hepatic blood flow and vascular resistance. Portal hypertension is a major complication in liver disease caused by increased intrahepatic vascular resistance mediated in part by a reduction in eNOS derived NO ([@B20]); cirrhotic livers also present with significantly reduced hepatic eNOS activity ([@B52]; [@B58]), while NAFLD patients across varying degrees of severity show marked hepatic eNOS dysfunction ([@B48]).

There is also limited evidence indicating that loss of eNOS is associated with increased hepatic steatosis. Double KO mice obtained from crossing obese leptin receptor deficient (*Leprdb/db*) mice crossed with eNOS KO mice exhibit elevated hepatic steatosis compared with *Leprdb/db* ([@B38]). Similarly, eNOS KO mice fed a 60% high fat diet for 12-weeks accumulate ∼25% more TAG than WT counterparts, a finding which the authors attributed to attenuated microsomal triglyceride transfer protein (TAG export) activity in eNOS KO mice ([@B45]). Finally, hepatic TAG accumulation was increased with 4 weeks of NOS inhibition with the non-selective NOS inhibitor (N^ω^ -nitro-L-arginine methyl ester; L-NAME), in hyperphagic OLETF rats ([@B62]). Moreover, we also have shown that reduced eNOS activation is associated with NAFLD progression ([@B60], [@B61]). Importantly, loss of eNOS activation, as well as NAFLD development, were prevented with chronic voluntary wheel running exercise, indicating a potential role for exercise-induced elevations in eNOS activity in liver health ([@B60]). The whole body eNOS null model coupled with evidence of reduced eNOS activation with NAFLD development demonstrates a potential protective role for eNOS in the pathogenesis of NAFLD ([Table 1](#T1){ref-type="table"}). However, these studies fail to define the role of hepatocyte-specific eNOS in this pathogenesis, as this enzyme is present in other cell types within the liver.

###### 

Manipulations of eNOS and their effects on NAFLD and mitochondrial outcomes in liver and other tissues.

  Authors   Model                                           Comments/outcomes
  --------- ----------------------------------------------- -------------------------------------------------------------------------------------------------------
  [@B26]    Whole body eNOS KO                              ↓ Mitochondrial content and β-oxidation in skeletal muscle vs. WT mice
  [@B59]    Whole body eNOS KO                              ↑ Hepatic insulin resistance vs. WT mice
  [@B45]    Whole body eNOS KO                              ↑ Hepatic steatosis, ↓ TAG export and hepatic blood flow vs. WT mice
  [@B38]    Double KO mice -- leptin receptor and eNOS KO   ↑ Hepatic steatosis vs. leptin KO only mice
  [@B62]    NOS inhibition via L-NAME                       ↑ Hepatic steatosis and stellate cell activation, ↓ hepatic mitochondrial function vs. OLETF controls
  [@B54]    Global eNOS overexpression                      ↓ Diet-induced obesity, ↑ mitochondrial function in adipose tissue vs. WT mice
  [@B70]    Whole body eNOS KO                              ↓ Exercise-induced mitochondrial biogenesis and content in adipose tissue vs. WT mice
  [@B74]    Whole body eNOS KO                              ↓ Exercise-induced mitochondrial biogenesis and content in cardiac tissue vs. WT mice
  [@B61]    eNOS KO hepatocytes                             ↓ Mitochondrial biogenesis, mitophagy, and fatty acid oxidation vs. control hepatocytes
  [@B55]    Systemic NO donor                               ↓ NASH progression via lower M1 macrophage polarization vs. WT mice
  [@B25]    Systemic NO donor                               ↓ NASH progression via increased hepatic stellate cell apoptosis
  [@B30]    Liver-specific NO donor                         ↓ Drug-induced hepatic oxidative stress and DNA damage vs. untreated control mice
  [@B37]    Liver-specific NO donor                         ↓ Bile duct ligation-induced hepatic fibrosis vs. placebo treated rats
  [@B32]    Liver-specific NO donor                         ↓ Hepatic steatosis and DNL vs. untreated control mice

↑, increased; ↓, decreased; KO, knockout; NOS, nitric oxide synthase; NO, nitric oxide; WT, wild-type; TAG, triglyceride; vs, versus; DNL,

de novo

lipogenesis.

Hepatocellular eNOS {#S1.SS5}
-------------------

Considerable discrepancy exists in the literature regarding the distribution of eNOS in the liver. In a seminal report, [@B57] demonstrated in rats that eNOS regulates sinusoidal perfusion and immunohistochemistry demonstrated its expression was restricted to liver endothelial cells. Based largely on this report, numerous subsequent studies on hepatic eNOS presume a mere endothelial localization of eNOS yet offer little, if any, supporting evidence ([@B57], [@B58], [@B56]; [@B46]). However, mounting evidence identifies a more ubiquitous eNOS distribution in the liver; [@B34] used immunohistochemistry and *in situ* hybridization to demonstrate widespread eNOS expression in human liver samples. In addition, [@B35], demonstrated an increase in eNOS S1177 phosphorylation in isolated primary hepatocytes following epidermal growth factor stimulation. Interestingly, eNOS was localized in the cytosol in a pattern consistent with hepatocyte mitochondrial distribution. Similarly, increased eNOS activation in isolated primary wild-type hepatocytes was observed with BH4 administration ([@B1]).

In one of the most comprehensive proteomic analysis of any organ to date, [@B2] used density gradient centrifugation and magnetic affinity cell sorting techniques to obtain highly purified murine hepatic cell types; hepatocytes, Kupffer cells, liver sinusoidal endothelial cells, hepatic stellate cells, and intrahepatic cholangiocytes. Using an advanced liquid chromatography tandem mass spectrometry approach, they clearly identified eNOS in their purified hepatocytes, with its highest expression in Kupffer cells and liver sinusoidal endothelial cells. Using the same methodology, our group has confirmed these findings by identifying eNOS expression in isolated primary hepatocytes from WT mice using magnetic-activated cell sorting and immunofluorescence ([@B61]). Taken together, these more recent and methodologically robust data strongly imply the presence of eNOS in hepatocytes.

Mitochondrial NOS {#S1.SS6}
-----------------

As a further confounder to the role of the NOS enzymes in hepatocytes, there is a body of evidence supporting the existence of mitochondrial NOS (mtNOS) that is present on the inner mitochondrial membrane. As there is no fourth NOS gene in mammalian genomes, mtNOS is thought to be a variant of one of the three known NOS isoforms. Initial reports identified eNOS as the mtNOS in skeletal muscle, brain, and liver ([@B3]; [@B23]). However, it was later demonstrated that eNOS physically associates with the outer leaflet of the outer mitochondrial membrane ([@B17]) and as such is not believed to be the "bona fide" mtNOS on the inner membrane ([@B18]). Instead, evidence exists to support both nNOS and iNOS as mtNOS. [@B47] demonstrated that the PDZ domain nNOS physically interacts with cytochrome c oxidase (COX) and used immunogold to identify nNOS in the inner mitochondrial membrane. Alternatively, [@B69] identified mtNOS as iNOS in purified rat liver mitochondria. Regardless of isoform or sub-mitochondrial localization, it is apparent that a NOS isoform is present in hepatic mitochondria and, given the current discussion, this may have significant implications in hepatic mitochondrial physiology. The influence and significance of "mtNOS" as it relates to NAFLD has not previously been addressed and is outside the scope of this mini review.

The Role of eNOS in Mitochondrial Dynamics and Function {#S2}
=======================================================

eNOS and Mitochondrial Respiration {#S2.SS1}
----------------------------------

How eNOS plays a role in NAFLD pathogenesis may be its function as a mediator of mitochondrial function. A key physiological role of eNOS (and other NOS enzymes) derived NO is its well-characterized interaction with COX in the mitochondrial ETC. NO inhibits COX via both competitive and non-competitive sites ([@B33]). Importantly, these inhibitory actions of NO on COX were demonstrated across both pathological and physiological spectrum of both NO and O~2~ concentrations. These data indicate that the rate of O~2~ consumption at a given \[O~2~\] is inversely proportional to \[NO\]. In addition, NO may influence other aspects of mitochondrial bioenergetics, including attenuation of complex I and III, which are known sites for ROS production through S-nitrosylation ([@B12]; [@B6]), and NO-dependent inhibition of the TCA cycle in rat hepatocytes ([@B64]). Thus, constitutive NO production may act to adjust mitochondrial respiration, in a manner similar to metformin -- which exerts its hepatic benefits by inhibiting mitochondrial respiration to increase hepatic AMPK activation ([@B29]). Taking hypoxia, a known activator of eNOS, as an example, such respiratory inhibition by NO would prevent excess O~2~ consumption by mitochondria closest to the O~2~ source and allow for more ubiquitous tissue O~2~ distribution. Similarly, in a fed condition, which activates eNOS via insulin mediated Akt activation, this NO throttle could reduce substrate oxidation in the most proximal mitochondria thus limiting the extent of ROS production in this microdomain. This function may be particularly relevant to the attenuation of mitochondrial derived ROS in NAFLD by attenuating electron transport flux and membrane potential in the face of increased ETC pressure from nutrient excess.

eNOS and Mitochondrial Biogenesis {#S2.SS2}
---------------------------------

The link between eNOS derived NO and its regulation of mitochondrial function in other tissues is well established. In a seminal paper by [@B43] the addition of an NO donor to cultured brown adipocytes induced markers of mitochondrial biogenesis and content in a cyclic GMP and peroxisome proliferator receptor γ coactivator α (PGC1α) dependent manner. In the same study, cold exposure-induced mitochondrial biogenesis in brown adipose tissue was significantly attenuated in whole body eNOS null mice, while eNOS null mice also presented with reduced markers of mitochondrial content in brain, heart, and liver tissue ([@B43]). Furthermore, calorie restricted-induced mitochondrial biogenesis is severely attenuated in eNOS null mice ([@B44]). The reverse is also true -- global eNOS overexpression prevented diet induced obesity while increasing markers of mitochondrial biogenesis and activity in adipose tissue ([@B54]). Additionally, TNFα-induced downregulation of eNOS expression impairs mitochondrial biogenesis and function in different tissues of obese rodents ([@B72]), further solidifying the link between eNOS and mitochondrial biogenesis. Interestingly, exercise-induced adaptations in mitochondrial health may be dependent on eNOS. In fact, 6 weeks of swim training increased mitochondrial biogenesis, mitochondrial DNA content, and glucose uptake in subcutaneous adipose tissue of wild-type but not eNOS KO mice ([@B70]). Similarly, genetic ablation of eNOS attenuated exercise-induced increases in mitochondrial biogenesis and function in cardiomyocytes ([@B74]). Collectively, these studies demonstrate a strong tie between eNOS and mitochondrial biogenesis ([Table 1](#T1){ref-type="table"}), and that exercise promotes eNOS dependent improvements in mitochondrial biogenesis and function.

eNOS and Autophagy/Mitophagy {#S2.SS3}
----------------------------

While there is clear evidence for a role of eNOS in the process of mitochondrial biogenesis, less is known about the ability of eNOS to regulate mitochondrial turnover. This turnover hinges on the intimately linked processes of biogenesis and autophagy -- where dysfunctional, aberrant mitochondria are removed via selected autophagy (mitophagy) and replaced in an effort to maintain mitochondrial homeostasis within the cell ([@B21]). Indeed, impaired mitophagy in the liver leads to accumulation of dysfunctional mitochondria, increased oxidative stress, and elevated steatosis ([@B13]). BNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3) is a cytosolic protein that docks to the outer mitochondrial membrane where it tags damaged mitochondria for autophagosomal engulfment and lysosomal degradation. Despite dramatically elevated hepatic mitochondrial mass in BNIP3 null mice, a large percentage of the mitochondria are damaged (have no membrane potential) and have defective mitochondrial β-oxidation capacity, and the animals develop hepatic steatosis ([@B19]).

The data on eNOS and autophagy/mitophagy are limited; however, there is strong evidence for NO regulation of autophagy. NO has consistently shown to be a potent activator of AMPK ([@B78]). This directly promotes autophagy/mitophagy by the AMPK-induced activation of Unc-51 Like Autophagy Activating Kinase 1 (Ulk1) at Ser 317 and Ser 777 ([@B22]) -- a key initiating step in the autophagosome formation. Indeed, NO stimulates autophagy in breast cancer cells by suppression of mTORC1 (Ulk1 inhibitor) and activation of AMPK ([@B71]). This resulted in elevated light chain 3 (LC3) II/I ratio and decreased p62 levels, indicative of increased autophagosome formation and ultimately its targeted degradation. Recent work from our lab has demonstrated hepatocellular eNOS as a novel regulator of mitochondrial homeostasis and maintaining mitophagic capacity ([@B61]). Hepatic mitochondria from eNOS null mice displayed decreased markers of mitochondrial biogenesis (PGC1α, TFAM) and autophagy/mitophagy (BNIP3, LC3II/I). In addition, *in vitro* siRNA-induced knockdown of eNOS in primary hepatocytes reduced fatty acid oxidation and impaired the induction of BNIP3 upon mitophagic stimulation. Collectively, these data demonstrate a novel role for hepatocellular eNOS in maintaining a healthy mitochondrial pool within the hepatocyte and may contribute to curbing NAFLD development ([Figure 2](#F2){ref-type="fig"}). Further *in vivo* manipulation of hepatocellular eNOS is required to tease out its significance in hepatic mitochondrial dynamics and NAFLD development.

![Schematic illustration of the potential role that hepatocellular endothelial nitric oxide synthase (eNOS) may play in non-alcoholic fatty liver disease (NAFLD) development. Genetic ablation of eNOS in mice, as well as small interfering RNA (siRNA) knockdown (KD) of eNOS in isolated primary hepatocytes result in hepatocytes lacking eNOS. This leads to a reduction in markers of hepatic mitochondrial biogenesis \[PPARγ coactivator-1α (PGC-1 α), mitochondrial transcription factor A (TFAM)\], and also markers of autophagy/mitophagy \[BCL-2-interacting protein-3 (BNIP3), 1A/1B light chain 3B (LC3)\], and decreased fatty acid oxidation in primary hepatocytes \[as measured by complete ^14^Co~2~ production ([@B61])\]. Whether this process is governed by a reduction in nitric oxide (NO) is yet to be determined. This impairment in hepatic mitochondrial dynamics can lead to mitochondrial dysfunction, and ultimately may cause/exacerbate NAFLD development.](fphys-11-00767-g002){#F2}

eNOS and Advanced Liver Disease {#S2.SS4}
-------------------------------

Our lab has recently demonstrated that normal hepatic eNOS activation is dramatically reduced in the obese OLETF rat during the transition from hepatic steatosis to NASH ([@B60]), implicating the loss of normal eNOS function in the advancement of liver disease. In a follow-up study, treating obese OLETF rats with L-NAME for 4 weeks caused reduced hepatic mitochondrial respiration, increased hepatic TAG accumulation, and induced a more NASH-like phenotype (increased stellate cell and Kupffer cell activation markers) compared with untreated obese controls ([@B62]). These studies support previous work implicating reduced eNOS activity and NO production in the activation of Kupffer cells and hepatic stellate cells ([@B68]; [@B77]).

On the other hand, increasing NO bioavailability may provide some hepatoprotection against metabolic insults. Giving a systemic NO donor has recently been shown to attenuate NASH progression, in part through lowering M1 macrophage polarization ([@B55]) and promotion of hepatic stellate cell apoptosis ([@B25]). Perhaps more encouraging, initial studies with a liver-selective NO donor, V-PVRRO/NO, which avoids the potential confounding factors of systemic NO delivery, including hypotension, have shown protection against drug induced ([@B30]) and bile duct ligation induced liver injury ([@B37]) and also reduced high fat diet induced hepatic steatosis by \>50% ([@B32]). Targeting eNOS may also be a strategy for attenuating NASH development; mice treated with relaxin-2 increased hepatic eNOS activation and attenuated Kupffer cell and stellate cell activation in methionine--choline-deficient (MCD) diet-induced NASH ([@B27]). Collectively, these data demonstrate an association between loss of hepatic eNOS function and NASH. Importantly, increasing hepatic eNOS and NO shows promise as a potential therapeutic to curb advanced liver disease progression, possibly by attenuating hepatic inflammation ([Table 1](#T1){ref-type="table"}). Future studies overexpressing hepatocellular eNOS in the face of a liver insult would help identify its role in mitigating NASH development.

Conclusion {#S3}
==========

Significant strides have been made in recent years in teasing out the molecular mechanisms of NAFLD development and progression, including the pathological role of hepatic mitochondrial dysfunction. Given the well characterized role of eNOS in mitochondrial dynamics in an array of tissues, including exercise-induced mitochondrial adaptations, one could speculate that eNOS is also functioning to maintain a healthy mitochondrial pool in hepatocytes ([Figure 1](#F1){ref-type="fig"}). Indeed, data from our group have identified a novel role for hepatocellular eNOS in NAFLD development and furthers our understanding of the molecular mechanisms involved in NAFLD pathogenesis ([Figure 2](#F2){ref-type="fig"}). Future studies should seek to further elucidate the role of hepatocellular eNOS via direct manipulation, i.e., *in vivo* hepatocyte-specific gain and loss of function studies, and whether hepatocellular eNOS is required for hepatic mitochondrial adaptations to exercise. Uncovering a role for hepatocellular eNOS may improve our knowledge of NAFLD pathogenesis, but more importantly, also may provide a potential therapeutic target to attenuate hepatic mitochondrial dysfunction and curb NAFLD development.
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